It's hard to speculate on that given we have no notion to the new trial outcomes. But since they are a bit smaller is it possible they provide stock as a supplement to whatever buyout price is decided upon? It seems feasible, but I wonder if WP would go for that considering they probably would like an outright cash deal.
They have a 500mm market cap and 160mm+ in cash and a pipeline that c/b valued(per analysts)at 3B assuming commercialization and clinical success. Would think they could put together $200-$250mm offer.
http://wsw.com/webcast/jmp21/SPPI/ forward to 10:53 into the meeting and he says they are currently working on several potential deals to bring new assetes to the company. Bad thing is he says it could even be done this year. I cant wait another day much less someone saying "maybe even this year"
Market Data 
Markets 
AI
